Three states filed a lengthy complaint Thursday in Amarillo federal court reviving the dormant lawsuit challenging looser restrictions on the use of an abortion drug.
A federal judge in Texas is allowing three other states to pursue a challenge seeking to restrict access to the abortion pill mifepristone nationwide.
Three Republican-led states will be allowed to move forward with a lawsuit to restrict access to mifepristone, a Texas federal judge ruled Thursday, months after the Supreme Court rejected an
A federal judge in Texas ruled that three states can challenge the current rules of accessibility for abortion pills.
The Republican-led states of Idaho, Missouri and Kansas can proceed with a lawsuit seeking to restrict the availability of the abortion pill mifepristone
Instead of dismissing the case, Judge Matthew Kacsmaryk said three states with no connection to Texas can sue the FDA to try to reimpose restrictions on mifepristone.
Trump-appointed Judge Matthew Kacsmaryk ruled Thursday that Idaho, Kansas, and Missouri can pursue legal action to prohibit the FDA from allowing online prescriptions.
File video above: Supreme Court preserves access to abortion medication Mifepristone The states of Idaho, Kansas and Missouri made the request in U.S. District Court in Amarillo, Texas.
Missouri, Kansas and Idaho can press forward with their lawsuit to restrict access to the abortion drug mifepristone, a federal judge ruled Thursday, months after the US Supreme Court had rejected an earlier version of the legal challenge.
It’s freezing out here, but our hearts are on fire,” said one participant in Amarillo's demonstration held over the weekend.
President-elect Trump campaigned on leaving abortion decisions to the states, but that could prove a tough promise to keep as he returns to the Oval Office. Anti-abortion groups want Trump
The Trump-appointed federal judge who unilaterally ordered the FDA to revoke approval of an abortion drug allowed Idaho, Kansas and Missouri to move forward in another lawsuit over mifepristone.